Bio-Rad Laboratories Inc. (BIO)
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $1.89 per share, missing the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.54 per share a year ago.
Boston Trust Walden Corp Lowers Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
Boston Trust Walden Corp decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,838 shares of the medical research company's stock after selling 5,610 shares during the period. Boston
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.
Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of oilfield equipment, technology and expertise, and First Citizens, a North Carolina-based bank. Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas.
